指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者的消化道出血预防:临床实践指南

Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline.
指南 / 共识 · BMJ · 2020-01-06
一句话结论该指南弱推荐对临床重要消化道出血高风险(>4%)的重症患者进行预防,低风险(≤4%)者弱推荐不预防;建议首选PPI而非H2RA(弱推荐),反对使用硫糖铝(强推荐)。

该指南由包含患者、临床医生和方法学家的专家组采用GRADE方法制定,基于一项纳入72项试验、12660例重症患者的系统评价与网状Meta分析。PPI和H2RA均降低临床重要出血风险,在高出血风险患者中效应更大;PPI可能比H2RA更降低出血风险,但可能增加肺炎风险,对死亡率可能无影响。指南弱推荐对临床重要出血风险>4%的重症患者使用预防,≤4%者弱推荐不使用;建议使用PPI而非H2RA(弱推荐),反对使用硫糖铝(强推荐)。

要点

  • 临床重要消化道出血风险>4%的重症患者,弱推荐使用消化道出血预防;风险≤4%者弱推荐不使用。
  • 高出血风险因素包括:凝血障碍、慢性肝病、或机械通气但未肠内营养、或机械通气加肠内营养、急性肾损伤、脓毒症、休克中两项或以上。
  • 建议使用PPI而非H2RA进行预防(弱推荐);反对使用硫糖铝(强推荐)。
  • PPI和H2RA可能增加肺炎风险(低确定性),对死亡率可能无影响(中等确定性)。
  • 决定是否预防时,应权衡出血风险降低与肺炎可能风险,并考虑患者价值观和药物可及性等因素。

适用人群与场景

  • 重症患者,依据临床重要消化道出血风险分层:高风险(>4%)与低风险(≤4%)。
  • 高出血风险因素包括凝血障碍、慢性肝病、或机械通气但未肠内营养、或机械通气加肠内营养、急性肾损伤、脓毒症、休克中两项或以上。

诊断标准与关键阈值

  • 以临床重要消化道出血风险>4%作为启动预防的阈值,≤4%作为不预防的阈值。

处置流程与药物剂量

  • 对临床重要消化道出血风险>4%的重症患者,弱推荐使用消化道出血预防。
  • 对临床重要消化道出血风险≤4%的重症患者,弱推荐不使用预防。
  • 建议使用PPI而非H2RA进行预防(弱推荐)。
  • 反对使用硫糖铝(强推荐)。

研究设计与关键结果

  • 链接的系统评价与网状Meta分析纳入72项试验、12660例重症患者,评估PPI和H2RA的获益与危害。
  • PPI和H2RA均降低临床重要出血风险,在高出血风险患者中效应更大(中等确定性)。
  • PPI和H2RA可能增加肺炎风险(低确定性),对死亡率可能无影响(中等确定性),对住院时间或其他重要结局可能无影响。
  • PPI可能比H2RA更降低出血风险(中等确定性)。

证据类型、等级与局限

  • 证据类型:临床实践指南,采用GRADE方法制定,基于链接的系统评价与网状Meta分析。
  • 推荐强度:弱推荐(高风险预防、低风险不预防、PPI优于H2RA);强推荐(反对硫糖铝)。
  • 风险因素证据确定性不一;出血获益中等确定性;肺炎风险低确定性;死亡率影响中等确定性。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对临床重要消化道出血风险>4%的重症患者,可考虑使用PPI或H2RA预防(弱推荐,两种选择均合理)。
  • 对临床重要消化道出血风险≤4%的重症患者,可考虑不使用预防(弱推荐)。
  • 选择药物时建议使用PPI而非H2RA(弱推荐),反对使用硫糖铝(强推荐)。
  • 决策时应考虑个体患者价值观、出血风险及药物可及性等因素。

指南或共识出处

  • 指南名称:Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline;发布于BMJ;年份原文未写明。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CLINICAL QUESTION: What is the role of gastrointestinal bleeding prophylaxis (stress ulcer prophylaxis) in critically ill patients? This guideline was prompted by the publication of a new large randomised controlled trial.

CURRENT PRACTICE: Gastric acid suppression with proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) is commonly done to prevent gastrointestinal bleeding in critically ill patients. Existing guidelines vary in their recommendations of which population to treat and which agent to use.

RECOMMENDATIONS: This guideline panel makes a weak recommendation for using gastrointestinal bleeding prophylaxis in critically ill patients at high risk (>4%) of clinically important gastrointestinal bleeding, and a weak recommendation for not using prophylaxis in patients at lower risk of clinically important bleeding (≤4%). The panel identified risk categories based on evidence, with variable certainty regarding risk factors. The panel suggests using a PPI rather than a H2RA (weak recommendation) and recommends against using sucralfate (strong recommendation).

HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, clinicians, and methodologists produced these recommendations using standards for trustworthy guidelines and the GRADE approach. The recommendations are based on a linked systematic review and network meta-analysis. A weak recommendation means that both options are reasonable.

THE EVIDENCE: The linked systematic review and network meta-analysis estimated the benefit and harm of these medications in 12 660 critically ill patients in 72 trials. Both PPIs and H2RAs reduce the risk of clinically important bleeding. The effect is larger in patients at higher bleeding risk (those with a coagulopathy, chronic liver disease, or receiving mechanical ventilation but not enteral nutrition or two or more of mechanical ventilation with enteral nutrition, acute kidney injury, sepsis, and shock) (moderate certainty). PPIs and H2RAs might increase the risk of pneumonia (low certainty). They probably do not have an effect on mortality (moderate certainty), length of hospital stay, or any other important outcomes. PPIs probably reduce the risk of bleeding more than H2RAs (moderate certainty).

UNDERSTANDING THE RECOMMENDATION: In most critically ill patients, the reduction in clinically important gastrointestinal bleeding from gastric acid suppressants is closely balanced with the possibility of pneumonia. Clinicians should consider individual patient values, risk of bleeding, and other factors such as medication availability when deciding whether to use gastrointestinal bleeding prophylaxis. Visual overviews provide the relative and absolute benefits and harms of the options in multilayered evidence summaries and decision aids available on MAGICapp.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Ye Z, Reintam Blaser A, Lytvyn L, et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020. PMID: 31907223. doi:10.1136/bmj.l6722

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。